Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a major risk for pulmonary hypertension with poor prognosis. Limited data is available on the optimal treatment of choice. We aimed to comprehensively assess the efficacy and safety of CTEPH targeted therapies and update the evidence.
Methods: We searched PubMed, Scopus, and the Cochrane library up to December 2023 to include randomized controlled trials comparing different therapies in patients with CTEPH. Primary outcomes were 6-minute walk distance (6 MWD), pulmonary vascular resistance (PVR), and mean pulmonary artery pressure (mPAP). While secondary outcomes were the mean right atrial pressure (mRAP), Borg dyspnea score, cardiac output (CO), cardiac index, adverse events, and all-cause mortality.
Results: Fourteen RCTs comprising 1047 patients were included in this network meta-analysis. Regarding 6 MWD, PADN (MD=113.59, 95% CI: 53.80; 173.39), BPA (MD=48.84, 95% CI: 27.99; 69.69), riociguat (MD=42.59, 95% CI: 22.01; 63.18), treprostinil (MD=41.60, 95% CI: 17.07; 66.13), and macitentan (MD=34.00, 95% CI: 3.50; 64.50) were favored compared to placebo. In terms of PVR, BPA (MD=-392.19, 95% CI: -571.77; -212.62), treprostinil (MD=-287.20, 95% CI: -475.63; -98.77), PADN (MD=-280.61, 95% CI: -506.69; -54.52), bosentan (MD=-176.00, 95% CI: -340.91; -11.09), and riociguat (MD=-171.61, 95% CI: -298.40; -44.81) displayed statistically significant results.
Conclusion: Current therapeutic modalities are effective in terms of improving exercise capacity, pulmonary hemodynamics, and reducing adverse events and all-cause mortality. Overall, BPA and PADN were superior to all other targeted medications in the studied outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470563 | PMC |
| http://dx.doi.org/10.1016/j.ahjo.2024.100466 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Generative artificial intelligence for automated data extraction from unstructured medical text.
JAMIA Open
October 2025
Division of Pulmonary and Critical Care, Brigham and Women's Hospital, Boston, MA, United States.
Objectives: Unstructured data, such as procedure notes, contain valuable medical information that is frequently underutilized due to the labor-intensive nature of data extraction. This study aims to develop a generative artificial intelligence (GenAI) pipeline using an open-source Large Language Model (LLM) with built-in guardrails and a retry mechanism to extract data from unstructured right heart catheterization (RHC) notes while minimizing errors, including hallucinations.
Materials And Methods: A total of 220 RHC notes were randomly selected for pipeline development and 200 for validation from the Pulmonary Vascular Disease Registry.
Impact of mode of delivery on maternal and fetal outcomes in pregnant patients with heart failure or pulmonary hypertension.
Am J Prev Cardiol
September 2025
Department of Cardiology, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, USA.
Background: Data on outcomes associated with various modes of delivery in pregnant patients with heart failure (HF) or pulmonary hypertension (pHTN) are limited.
Objective: We aim to investigate the association between mode of delivery on maternal and fetal outcomes in pregnant patients with HF or pHTN by conducting a multicenter, large scale and nationwide retrospective cohort study.
Methods: This retrospective population-based cohort study used the Nationwide Readmission Database to identify all hospitalized pregnant patients who were primarily admitted for vaginal or cesarean delivery from 2011 to 2019.
A Tale of Overlapping Autoimmune Serologies: Diagnosing Hydralazine-Induced Antineutrophilic Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) Related With Isolated Pulmonary Involvement.
Cureus
August 2025
Norton College of Medicine, SUNY Upstate Medical University, Syracuse, USA.
Hydralazine is an antihypertensive that can induce immune-related adverse effects, such as hydralazine-induced lupus and hydralazine-induced antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV). AAV involves necrotizing inflammation of small blood vessels, manifesting as fever, malaise, arthralgia, and myalgia, potentially leading to organ failure. Diagnosis includes clinical evaluation, serological testing for ANCA, and histopathological examination, confirmed by necrotizing granulomatous inflammation in affected tissues.
View Article and Find Full Text PDFAssociation Between Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Use and All-Cause Mortality in Patients With Pulmonary Arterial Hypertension.
Cureus
August 2025
Internal Medicine, Einstein Medical Center Philadelphia, Philadelphia, USA.
Introduction: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce mortality in heart failure patients with reduced and preserved ejection fraction. Their potential benefits in pulmonary arterial hypertension (PAH) are unknown. This study evaluates the relationship between SGLT2i use and all-cause mortality in patients with PAH.
View Article and Find Full Text PDFInverse association between pre-high-altitude potassium levels and coronary microvascular disease at high altitude: a case-control study.
Front Pharmacol
August 2025
Department of Cardiology, 920th Hospital of Joint Logistics Support Force of PLA, Kunming, China.
Background And Objectives: High-altitude hypoxia is known to impair cardiac microvascular function, a pathophysiological state recognized as coronary microvascular disease (CMVD). This study aimed to investigate the independent association between serum potassium levels and the risk of developing CMVD, after controlling for traditional cardiovascular risk factors such as hypertension, dyslipidemia, and smoking.
Methods: This case-control study enrolled 1,175 trainees with long-term exposure to high altitude (≥3,000 m), comprising 235 patients with CMVD (cases) and 940 healthy controls.